# 03_AI1_PRIMARY_INTERPRETATION

**Run:** PRICEPOINT-001  
**Stage:** 5 — Finish / Interpretation  
**Role:** AI 1 — Evidence Synthesis and Recommendation Builder  
**Pass:** Independent first pass  
**Mode:** SIMULATION / NON-LIVE  
**Bound Stage 4 receipt:** `9536fe9832310cb9b23f8af60862bf7b47b1a3c0b97939146e2d29543f3a664d`  
**Bound design:** `08_CONSOLIDATED_CANDIDATE_v5_4` / `3cfc71eb5e10c5f680e1768400d03daf05513a23199740ac9f80f8adff2b80ef`  
**Bound evidence bundle:** `evidence_pkg_v1.zip` / `fd1307c32111595f14e0737e6e48475c950da8ecf5dfbe27ed3071102904aee3`  
**Conclusion ceiling:** Predictive expectation only. No causal claim is permitted. The frozen package confirms the simulation status, bindings, locked population, capacity, guardrail, horizon, and backtest-collapse rule.

## File inventory

Files actually opened and examined for this interpretation:

* `01_STAGE_05_EVIDENCE_PACKAGE.v1.md`
* `evidence_pkg_v1/SHA256SUMS.txt`
* `framework/three-ai-interpretation-and-recommendation-framework.md` — especially §§3–22 and §24
* `locked/decision_statement_T035.txt`
* `locked/framing_question_C2.txt`
* `locked/08_CONSOLIDATED_CANDIDATE_v5_4.md`
* `locked/10_STAGE_03_MEASUREMENT_DESIGN.v5_4.md`
* `locked/11_STAGE_04_HANDOFF.v5_4.md`
* `locked/stage3_locked_design.v4.json`
* `stage4_outputs/audit.csv`
* `stage4_outputs/model_validation.json`
* `stage4_outputs/candidates.csv` — inspected only as a diagnostic artifact; its candidate predictions are not treated as decision-valid
* `stage4_receipts/fixtures.json`
* `stage4_receipts/model.json`
* `stage4_receipts/reconciliation.json`
* `stage4_receipts/stage4_validation_status.json`
* `stage4_receipts/validated_data_manifest.md`
* `stage4_receipts/validation.json`
* `stage4_receipts/workflow_gate_status.json`
* `stage4_review/cross_review.md`
* `stage4_review/findings_register.csv`
* `stage4_review/reconciliation.csv`
* `stage4_review/source_gate_report.csv`

No other AI's Stage 5 interpretation or audit was used.

---

## 1. Direct answer to the locked analytical question

**C-01 — Interpretation.** No specific pilot shelf-price raise, cut, or model-based unchanged decision is decision-valid for the locked 28-day cycle. Under §17.R8, the binding d_1913 backtest failed because A2 = `0.2697` was outside the permitted `[-0.20, +0.20]` range even though A1 = `0.1824` passed; consequently `backtest_accept = 0`, all `2,484/2,484` products are classified `hold_ne`, there are `0` legal price changes, `0` unchanged actions, `0` package changes, and `0` below-line opportunities. **Evidence status: Validated. Finding class: Conclusive for the defined question.** [R-01, R-04; `stage4_outputs/model_validation.json`, fields `primary.A1_median_ape`, `primary.A2_mean_signed_error`, `primary.backtest_accept`; `stage4_outputs/audit.csv`, fields `n_legal_changes`, `n_unchanged`, `n_hold_ne`, `n_package`, `n_below_line`]. The frozen evidence package records the same validated outcome.

**C-02 — Interpretation.** Confidence is **high** that `hold_ne` for all products and an empty GM price-change package are the correct outputs **under the locked design and validated Stage 4 execution**; this confidence does not mean that current prices are economically optimal or that no profitable individual price change exists. [R-01, R-04, R-05, R-06, R-07, R-08, R-09, R-10].

---

## 2. Strongest evidence

**C-03 — Computed result.** The strongest decision evidence is the binding d_1913 backtest: A1 median APE = `0.1824` passed its `≤ 0.40` threshold, while A2 mean signed error = `0.2697` failed the locked `[-0.20, +0.20]` interval, forcing `backtest_accept = 0`. **Evidence status: Validated.** [R-01; `stage4_outputs/model_validation.json`; `stage4_receipts/model.json`].

**C-04 — Computed result.** The locked consequence of that failure was fully realized in the judged output: `2,484/2,484 hold_ne`, `338` trust-eligible items nevertheless collapsed to `hold_ne`, `0` legal changes, `0` GM-package changes, and `0` below-line changes. **Evidence status: Validated.** [R-04; `stage4_outputs/audit.csv`; package result summary].

**C-05 — Observed fact.** Computational trust in the rule application is strong: independent R-A and R-B outputs reconciled `75/75` fields with `0` mismatches; the Source Gate passed `24/24`; frozen fixtures passed `26/26` on both paths; cross-review ended with `0` unresolved findings; and the Validation Gate was approved. **Evidence status: Validated.** [R-05, R-06, R-07, R-08, R-09].

**C-06 — Interpretation.** The nonbinding d_1885 stability origin gives contrary context because both reported metrics were within their acceptance limits there (`A1 = 0.1722`, `A2 = 0.1794`), so the evidence does not support describing model calibration as uniformly poor across origins; however, the lock explicitly makes d_1913 binding and d_1885 stability-only. **Evidence status: Validated. Finding class: Conflicting with respect to temporal calibration stability, but not conflicting with the locked current-cycle decision.** [R-01, R-02].

---

## 3. Hypothesis evaluation

The Stage 3 design labels one **Analytical hypothesis** and one **Mechanism** rather than explicitly naming separate “primary” and “secondary” hypotheses. To avoid inventing a new lock, I treat the analytical hypothesis as the primary hypothesis and the prespecified mechanism as the requested secondary proposition.

### Primary — Analytical hypothesis

**Locked proposition:** “Within-item log-price slope after calendar adjustment changes expected revenue ranking.”

**C-07 — Interpretation.** The primary analytical hypothesis is **weakened**, not rejected. The design explicitly lists a backtest miss—failure of A1 or A2 at d_1913—as a falsifier that weakens the hypothesis, and the binding A2 test failed. At the same time, the supplied validated Result Inventory R-01–R-10 does not include the prespecified A3/T6 price-plus-calendar versus calendar-only slope comparison, so this package does not justify the stronger conclusion that price variation itself lacks incremental predictive information. **Evidence status: Validated for the backtest failure; Inconclusive for the absent A3/T6 comparison.** [R-01; design §6.3 and §16.3].

**Evaluation:** **Weakened.**  
**Confidence:** High that it is weakened under the design's own falsifier rule; lower confidence about *why* it weakened.

### Secondary — Prespecified mechanism proposition

**Locked proposition:** “Historical within-item price variation contains predictive information about future demand response.”

**C-08 — Interpretation.** The mechanism proposition is **unresolved** from the supplied Stage 5 evidence. Overall calibration at the binding origin failed, which is adverse evidence, but the prespecified T6/A3 comparison needed to isolate whether price history adds predictive ranking information beyond calendar-only information is not supplied among R-01–R-10. Claiming that price history does or does not add predictive information would therefore exceed the package. **Evidence status: Inconclusive. Finding class: Inconclusive.** [R-01; design §6.2–§6.3; absence of an A3/T6 Result ID].

**Evaluation:** **Unresolved.**  
**Required follow-up:** **Recompute in Stage 4** if A3/T6 was not executed or package the validated existing A3/T6 output if it exists outside this bundle.

---

## 4. What the evidence does not establish

**C-09 — Interpretation.** The evidence does **not** establish that any price change causes a revenue or unit outcome; the locked ceiling is predictive expectation, and the accepted design limitations explicitly preserve possible price endogeneity, unlabeled promotions, and other unmeasured influences. [Design §§5, 14, 26.3].

**C-10 — Interpretation.** The evidence does **not** establish that the current shelf price is optimal for all 2,484 products, nor that no individual candidate price could improve revenue. It establishes instead that the locked model failed the trust condition required to make those item-level decisions. The `3,654` candidate rows remain diagnostic and are specifically not decision-valid after collapse. **Evidence status: Validated with limitation.** [R-01, R-04, R-10].

**C-11 — Interpretation.** The evidence does not establish that the model will fail at every future origin: the d_1885 stability check passed both reported criteria, while the binding d_1913 origin failed A2. [R-01, R-02].

---

## 5. Most important caveat

**C-12 — Interpretation.** The most important caveat is that the all-`hold_ne` result is a **global trust collapse**, not 2,484 independent findings that each current price is preferable. The decision rule deliberately sacrifices potentially useful item-level candidate information when the binding system-level calibration test fails. [R-01, R-04, R-10; design §16.4/§17.R8].

This distinction must remain beside the recommendation: **“no price changes are decision-valid” is supported; “there are no good price changes” is not.**

---

## 6. Decision-Option Matrix

| Claim | Option | Evidence required | Evidence observed | Benefit / downside / uncertainty | Capacity / guardrail | Verdict |
| --- | --- | --- | --- | --- | --- | --- |
| **C-13** | **Raise** | Accepted binding backtest; trust eligibility; legal candidate; positive rounded revenue delta; `rho ≥ 0.90`; ranked within capacity where applicable | Binding backtest failed and collapse produced `n_raise = 0`, `n_legal_changes = 0` | A raise could theoretically improve revenue, but current candidate predictions cannot support that decision | No capacity slot may be used; guardrail cannot rescue an action invalidated by R8 | **Reject for this cycle** [R-01, R-04] |
| **C-14** | **Cut** | Same decision-validity requirements as raise | Binding backtest failed; `n_cut = 0`, `n_legal_changes = 0` | A cut could theoretically improve revenue, but no cut is decision-valid under the locked model | No capacity slot may be used | **Reject for this cycle** [R-01, R-04] |
| **C-15** | **Unchanged** | Under R7, a trusted model can return unchanged where no legal candidate exists; under R8, model-based unchanged is also collapsed if backtest fails | `n_unchanged = 0`; R8 converts applicable model-based unchanged outcomes to `hold_ne` | Operational prices will remain where they are if no change is made, but the analytical label cannot be changed from `hold_ne` to `unchanged` | No capacity use | **Reject as an analytical action label this cycle** [R-01, R-04; design §17.R8] |
| **C-16** | **hold_ne** | Insufficient trusted evidence under the locked rule, including failed A1/A2 backtest | A2 failed; all `2,484` rows are `hold_ne` | Preserves the evidence threshold and avoids acting on untrusted predictions; downside is foregone opportunity if some diagnostic candidates would actually perform well | `0/25` price-change slots used; guardrail remains binding for any later eligible action | **Act — apply to all 2,484 products** [R-01, R-04] |
| **C-17** | **Pilot price changes now** | At least one decision-valid raise/cut after all trust and guardrail rules | None; diagnostic candidate rows are invalidated for decision use | A pilot is reversible, but using collapsed predictions would bypass the locked trust requirement | Would consume capacity without valid qualification | **Reject for this cycle** [R-04, R-10] |
| **C-18** | **Monitor** | A defined future review signal that can restore or further weaken trust | Temporal calibration differs between d_1885 and d_1913 | Monitoring is useful for determining whether the failure persists, but it does not authorize a current price decision | No price-change capacity required | **Monitor** [R-01, R-02] |
| **C-19** | **Collect more evidence** | Evidence targeted at the binding failure and missing prespecified hypothesis test | A2 failed; A3/T6 is absent from supplied R-01–R-10 | Directly addresses the reason actions were blocked and the unresolved mechanism proposition | No current capacity use | **Collect evidence; Recompute in Stage 4** |
| **C-20** | **No price action** | Current decision rules produce no valid change | Package = `0`; below-line = `0`; legal changes = `0` | Avoids acting on an unaccepted predictive system; may forgo profitable opportunities | Fully fits capacity; no change can violate the predicted-unit guardrail | **No action on shelf prices this cycle** [R-04] |

---

## 7. Primary recommendation

**C-21 — Recommendation.** **Morgan Lee should recommend to the California pilot store GM that no shelf-price changes be placed in the d_1942–d_1969 review-cycle package, that all 2,484 reviewed products retain the analytical action** `hold_ne`**, and that none of the diagnostic candidate prices be promoted into the GM package.** The package therefore contains **0 of the maximum 25 changes**. Any future price-change recommendation must still satisfy the locked `rho ≥ 0.90` guardrail and all other locked trust and legal-change rules. [R-01, R-04, R-10].

**Who:** Morgan Lee, Pricing & Revenue Manager, recommends; the store GM retains final organizational authority.  
**What:** Zero price changes; all 2,484 products reported as `hold_ne`.  
**Where:** CA_1, FOODS_1/2/3 and HOUSEHOLD_1/2.  
**When:** Locked horizon d_1942–d_1969, 2016-05-23 through 2016-06-19.  
**Capacity:** `0/25` actual price changes.  
**Evidence threshold:** The binding backtest must satisfy both A1 and A2 before model-based recommendations can survive §17.R8.  
**Guardrail:** Any later legal candidate must retain `rho ≥ 0.90`.  
**Expected benefit:** Avoids implementing price decisions from a predictive system that failed its prespecified trust criterion.  
**Exception path:** There is no Stage 5 exception that permits bypassing §17.R8. A defective lock must return to its owning earlier stage; a needed new calculation is **Recompute in Stage 4**.  
**Confidence:** **High** for this recommendation under the locked framework.

**C-22 — Recommendation caveat.** The recommendation should be presented as **“the model is not sufficiently trusted for a price decision this cycle,” not “current prices are proven best.”** The global collapse prevents decision use of item-level diagnostic predictions even where they appear favorable. [R-01, R-04, R-10].

---

## 8. Monitoring plan

Because this recommendation implements no price changes, there are no exposed pilot units and therefore no valid current-cycle treatment-effect or pilot-rollback assessment. Monitoring should focus first on whether the predictive decision system regains the prespecified level of trust.

| Element | Monitoring contract |
| --- | --- |
| **C-23 — Primary readiness metrics** | At the next approved Stage 4 evaluation, report the locked A1 median APE and A2 mean signed error. **Success:** A1 `≤ 0.40` **and** A2 within `[-0.20,+0.20]`. **Failure:** either test fails. These thresholds are locked, not newly chosen here. |
| **C-24 — Primary business metric** | If and only if a later price pilot becomes decision-valid and is authorized, the locked business KPI remains 28-day predicted/observed product revenue defined as units × shelf price. No current pilot outcome exists because this recommendation changes no prices. |
| **C-25 — Guardrail** | For any later candidate recommendation, retain locked `rho ≥ 0.90`; no Stage 5 relaxation is permitted. |
| **C-26 — Success trigger** | A future validated Stage 4 run passes both binding backtest criteria and produces legal change candidates through the unchanged locked rule; only then may Stage 5 evaluate a nonempty GM package. |
| **C-27 — Failure trigger** | If either binding backtest criterion fails again, retain `hold_ne` for trust-eligible items under §17.R8 and do not elevate diagnostic candidates. |
| **C-28 — Escalation trigger** | Escalate to Stage 4 if the A2 failure requires diagnosis or if the prespecified A3/T6 comparison is not available for hypothesis evaluation. **Recompute in Stage 4.** Escalate to Stage 3 only if investigation identifies a defect in a locked metric, threshold, population, model-evaluation contract, or decision rule rather than an execution issue. |
| **C-29 — Rollback trigger** | **Not applicable to this cycle:** zero shelf-price changes are recommended, so there is no implemented price intervention to roll back. The supplied locks do not define a separate post-implementation live rollback threshold, and Stage 5 must not invent one. |
| **Owner** | Morgan Lee owns the decision review. The human analyst owns acceptance of Stage 5 synthesis and any escalation. Stage 4 recomputation must be returned to the Stage 4 process rather than performed inside this interpretation. |
| **Timing** | Review on the next four-week decision cycle or after an approved Stage 4 recomputation supplies the required validated evidence, whichever is the applicable governed path. |

---

## 9. Next analytical question

**C-30 — Interpretation / next question.** **Why did the binding d_1913 backtest produce A2 mean signed error =** `0.2697` **while A1 passed and the earlier d_1885 stability origin also had A2 within the acceptance range, and—under the unchanged Stage 3 design—does a validated re-execution still fail A1/A2 and what does the prespecified T6/A3 price-plus-calendar versus calendar-only comparison show?**

**Why this matters:** It separates a potentially origin-specific calibration problem from a more general failure of the predictive system and supplies the missing evidence needed to evaluate whether within-item price variation adds useful ranking information.

**Disposition:** **Recompute in Stage 4.** No answer is inferred here.

---

## 10. Weakest bridge in my reasoning

**C-31 — Interpretation.** The weakest bridge is the move from the conclusive current-cycle `hold_ne` result to the process recommendation to collect additional evidence before the next decision. The evidence strongly determines what **not** to do now, but it does not establish which technical remediation, if any, will make the model trustworthy later; moreover, the absence of a supplied A3/T6 result prevents a complete diagnosis of whether the weakness lies in overall calibration, the incremental value of price information, or another model component. Confidence in the current no-change decision is therefore higher than confidence in the proposed analytical follow-up path. [R-01, R-02; design §6.3].

---

## Finding Ledger

| Finding ID | Exact proposition | Supporting Result IDs | Contrary Result IDs | Status | Conclusion type | Confidence | Decision relevance | Limitation |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **F-01** | The binding d_1913 backtest was not accepted because A2 = 0.2697 failed its locked interval although A1 = 0.1824 passed. | R-01 | R-02 is stability-only | **Conclusive** | Predictive | High | Activates §17.R8 | One binding origin does not establish permanent model failure |
| **F-02** | The locked current-cycle output is 2,484/2,484 `hold_ne`, zero legal changes, zero package changes and zero below-line changes. | R-04 | None | **Conclusive** | Predictive / decision-rule output | High | Directly answers C2 | Says nothing about whether individual diagnostic candidates would succeed |
| **F-03** | Calibration evidence differs by origin: d_1913 fails A2 while d_1885 passes both reported criteria. | R-01, R-02 | — | **Conflicting** | Predictive | High | Supports caution about temporal stability | d_1885 is explicitly nonbinding |
| **F-04** | Independent execution and validation strongly support that the locked rule was implemented as approved. | R-05, R-06, R-07, R-08, R-09 | None unresolved | **Conclusive** | Descriptive / audit | High | Makes implementation error a weaker explanation for the final action | Audit agreement does not make a poorly calibrated model decision-valid |
| **F-05** | The Stage 3 analytical hypothesis is weakened because its prespecified “backtest miss” falsifier occurred. | R-01 | R-02 provides limited contrary stability context | **Conclusive for the locked hypothesis-evaluation rule** | Predictive interpretation | High | Prevents strong positive interpretation of the price-ranking hypothesis | Does not isolate price information from other model components |
| **F-06** | The mechanism proposition that historical within-item price variation adds predictive information is not resolved by the supplied bundle because A3/T6 is absent from R-01–R-10. | R-01 plus design requirement | No supplied validated A3/T6 result | **Inconclusive** | Predictive | Medium-high | Blocks a stronger claim about the value of price history | **Recompute in Stage 4** if no validated result exists |
| **F-07** | The 3,654 diagnostic candidate rows cannot support a current raise or cut after the backtest collapse. | R-10, R-01, R-04 | None | **Conclusive** | Predictive | High | Prevents cherry-picking attractive candidate predictions | Diagnostic predictions can still guide later investigation |
| **F-08** | A claim that no individual profitable price change exists is not established. | R-10, R-04 | — | **Unsupported** if asserted | Predictive | High | Prevents overstatement of the no-action result | The design deliberately suppresses individual decisions after global collapse |
| **F-09** | A causal claim that a price change will cause the modeled revenue outcome is not established. | Design conclusion ceiling and accepted limitations | None | **Unsupported** if asserted | Causal | High | Restricts executive wording to predictive expectation | Competitor price, inventory, cost, margin, and unlabeled promotions are outside the model |
| **F-10** | No live pilot rollback threshold can be supplied from the current locked package because no current intervention is recommended and no separate live rollback rule is specified. | R-04; framework §22; locked design | None | **Conclusive for this package** | Descriptive / governance | High | Prevents Stage 5 from inventing a new operational threshold | An upstream stage may define one for a later live pilot |

---

## Claim-to-Evidence Ledger

| Claim ID | Final wording / proposition | Claim type | Evidence | Independent check | Assumptions | Limitation | Evidence status | Claim status |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **C-01** | No raise, cut, or model-based unchanged action is decision-valid; all 2,484 items are `hold_ne` and the package is empty. | Interpretation | R-01, R-04; `model_validation.json`; `audit.csv` | R-05, R-09 | Locked §17.R8 governs | Does not prove current prices optimal | **Validated** | Approved |
| **C-02** | Confidence is high in the locked current-cycle classification, not in economic optimality of current prices. | Interpretation | R-01, R-04–R-10 | Stage 4 validation spine | Locked rule accepted | Economic truth exceeds evidence | **Validated with limitation** | Approved |
| **C-03** | A1 passed and A2 failed at d_1913, forcing `backtest_accept=0`. | Computed result | R-01 | R-A/R-B agreement in R-05 | Locked thresholds | Binding-origin result only | **Validated** | Approved |
| **C-04** | Collapse produced 2,484 holds, including the trust-eligible population, with no legal/package changes. | Computed result | R-04 | R-05 | §17.R8 | Global collapse masks item heterogeneity | **Validated** | Approved |
| **C-05** | Reconciliation, source, fixtures, cross-review, and Validation Gate support computational trust. | Observed fact | R-05–R-09 | Multiple independent Stage 4 controls | Approved receipts are current | Computational trust ≠ model acceptance | **Validated** | Approved |
| **C-06** | d_1885 provides contrary stability context but is nonbinding. | Interpretation | R-01, R-02 | Same model receipts | Stability origin is reporting-only | Only two reported origins | **Validated** | Approved |
| **C-07** | The analytical hypothesis is weakened, not rejected. | Interpretation | R-01; design §6.3 | Design falsifier mapping | Backtest miss is a prespecified weakening condition | A3/T6 absent | **Validated with limitation** | Approved |
| **C-08** | The mechanism proposition is unresolved because incremental price information is not isolated in the supplied Result IDs. | Interpretation | Design §6.2–6.3; R-01; absence of A3/T6 | None supplied for A3/T6 | A3/T6 is the prespecified slope check | Requires upstream result | **Inconclusive** | Approved |
| **C-09** | No causal effect is established. | Interpretation | Design ceiling and limitations | Stage 3 lock | Predictive design | Cannot explain causal mechanism | **Validated with limitation** | Approved |
| **C-10** | Current-price optimality and absence of profitable individual changes are not established. | Interpretation | R-04, R-10 | R-05 | Collapse supersedes diagnostics | Individual counterfactual truth unknown | **Validated with limitation** | Approved |
| **C-11** | Model failure at every future origin is not established. | Interpretation | R-01, R-02 | Same model framework | Stability result comparable as reporting context | d_1885 nonbinding | **Conflicting** | Approved |
| **C-12** | The all-hold outcome is a global trust collapse, not 2,484 separate optimal-price conclusions. | Interpretation | R-01, R-04, R-10; §17.R8 | R-05 | Collapse rule applied as locked | Does not quantify foregone opportunities | **Validated** | Approved |
| **C-13** | Raise is rejected for this cycle. | Recommendation | R-01, R-04 | R-05 | Locked rules | No claim about future raises | **Validated** | Approved |
| **C-14** | Cut is rejected for this cycle. | Recommendation | R-01, R-04 | R-05 | Locked rules | No claim about future cuts | **Validated** | Approved |
| **C-15** | `unchanged` is not the valid analytical action label this cycle. | Interpretation | R-04; §17.R8 | R-05 | Collapse applies to model-based unchanged | Operational prices still physically remain unchanged | **Validated** | Approved |
| **C-16** | `hold_ne` applies to all 2,484 products. | Recommendation / result | R-04 | R-05, R-09 | Locked decision rule | Not equivalent to “bad candidate” | **Validated** | Approved |
| **C-17** | Current price pilots should not be launched from the collapsed candidate predictions. | Recommendation | R-04, R-10 | Stage 4 validation | Decision-validity requirement retained | Does not rule out later authorized pilot | **Validated** | Approved |
| **C-18** | Calibration should be monitored at a later governed evaluation. | Recommendation | R-01, R-02 | — | Another review occurs under governed process | Exact future outcome unknown | **Validated with limitation** | Approved |
| **C-19** | Additional evidence should target the A2 failure and missing A3/T6 result. | Recommendation | R-01; design §6.3 | — | These are decision/hypothesis-relevant gaps | Specific remediation not established | **Inconclusive** | Approved |
| **C-20** | No shelf-price action is appropriate this cycle. | Recommendation | R-04 | R-05, R-09 | Current locks stand | May forgo opportunities | **Validated** | Approved |
| **C-21** | Morgan should submit a zero-change GM package and preserve all 2,484 `hold_ne` classifications. | Recommendation | R-01, R-04, R-10 | R-05–R-09 | Current cycle only | Not a statement of price optimality | **Validated** | Approved |
| **C-22** | The recommendation means “insufficient model trust,” not “current prices are best.” | Interpretation | R-01, R-04, R-10 | — | Collapse semantics | Individual candidate truth unknown | **Validated with limitation** | Approved |
| **C-23** | Future readiness success requires A1 ≤ 0.40 and A2 within [-0.20,+0.20]. | Observed fact / recommendation | Locked §16.3 | Stage 4 model receipt | Thresholds remain locked | Does not itself guarantee future business success | **Validated** | Approved |
| **C-24** | The primary business KPI remains 28-day product revenue if a later authorized pilot occurs. | Observed fact | Design §10 | Stage 3 lock | No KPI redesign | No current exposed pilot | **Validated** | Approved |
| **C-25** | Future candidates remain subject to `rho ≥ 0.90`. | Observed fact | Locked guardrail | Stage 3 lock | No threshold change | Predictive, not causal | **Validated** | Approved |
| **C-26** | Only a future validated pass can reopen nonempty candidate-package evaluation. | Interpretation | §17.R8; R-01 | Stage 4 workflow gate | Same governance remains | Future data/model may differ | **Validated** | Approved |
| **C-27** | Another failed binding backtest requires continued collapse under the current lock. | Interpretation | §16.4/§17.R8 | Frozen fixtures include collapse rule | Lock unchanged | Future redesign could alter rule only upstream | **Validated** | Approved |
| **C-28** | Diagnosis of A2 or missing A3/T6 belongs in Stage 4; defective locks belong to their owning earlier stage. | Recommendation / governance | Framework §4; user rule; design | — | No silent lock repair | Exact defect not yet established | **Validated with limitation** | Approved |
| **C-29** | No current intervention exists to roll back, and no new live rollback threshold should be invented. | Interpretation | R-04; framework §22 | — | Zero price changes | Future pilot needs its own governed monitoring contract | **Validated** | Approved |
| **C-30** | The next question should diagnose the d_1913 signed-error failure and obtain the prespecified A3/T6 evidence under the unchanged design. | Recommendation | R-01, R-02; design §6.3 | — | Investigation stays upstream | **Recompute in Stage 4** | **Inconclusive pending recomputation** | Open |
| **C-31** | The weakest bridge is from a certain current hold decision to an uncertain choice of what analytical remediation will restore trust. | Interpretation | R-01, R-02; absence of A3/T6 | — | Follow-up is a judgment, not current decision output | No remediation effectiveness has been validated | **Inconclusive** | Approved as disclosed limitation |

---

## Final AI 1 conclusion

The Stage 5 interpretation is narrower than the diagnostic predictions might initially suggest. The current evidence is strong enough to answer the locked operational question decisively but not strong enough to identify any valid price change: the binding model-validation criterion failed, the collapse rule was correctly executed, and every product is therefore `hold_ne`. The defensible recommendation is an empty GM price-change package for this cycle, accompanied by explicit disclosure that this is a failure of decision trust rather than proof that existing prices are optimal.

The next useful work is upstream: determine why the binding signed-error criterion failed and supply the prespecified A3/T6 evidence without altering the Stage 3 locks inside Stage 5.

END 03_AI1_PRIMARY_INTERPRETATION
